Oral formulation of Prussian blue with improved efficacy for prophylactic use against thallium

10.1016/j.jpba.2007.11.049

U. S. Food and Drug Administration. Prussian blue drug products- submitting a new drug application. 2003 [cited 2021 Oct 28]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidancedocuments/prussian-blue-drug-products-submitting-new-drug-application

10.1155/2017/4875784

10.1345/aph.1E024

10.1016/B978-012373738-0.50015-5

10.2147/ODRR.S31881

10.1055/s-0032-1331755

Lee I, 2018, Sci Rep, 8, 1

10.1016/j.jhazmat.2010.06.019

10.1097/00004032-199101000-00009

Lipsztein JL, 1990, Health Phys, 60, 5

10.1097/00004032-199101000-00006

10.1097/00004032-199101000-00008

10.1016/B978-0-12-803072-1.00005-5

10.3390/ijms22020780

10.1097/01.HP.0000180771.66884.d3

10.1016/j.scitotenv.2013.10.029

10.2174/1567201818666210127093327

10.1016/j.ijpharm.2019.118600

10.1016/j.jsps.2015.02.018

Mittal P, 2019, Indian Chemical Society, 96, 641

Lau E., 2001, Separation science and technology, 173

IPC, 2010, Indian Pharmacopoeia, 1

10.1007/s10811-020-02052-0

10.1007/s10811-021-02640-8

2022, . International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use

United State Food and Drug Administration (USFDA). Guidance for industry Q1A (R2) stability testing of new drug substances and products. 2003;2(1):1–22. [cited 2021 Oct 25]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q1ar2-stability-testing-new-drug-substances-and-products

10.14227/DT250318P30

10.1248/cpb.52.704

Sakr AM, 1978, Pharm Ind, 40, 1080

10.1016/S0928-0987(01)00095-1

10.1016/S0001-2998(80)80030-4

10.1007/s13181-012-0251-1

Yumoto T, 2017, J Clin Diagn Res, 11, OD01

Rowe RC, 2009, Handbook of pharmaceutical excipients, 6